Extended retreatment with brentuximab vedotin (SGN-35) maintains complete remission in patient with recurrent systemic anaplastic large-cell lymphoma

Kelley V. Foyil, Dana A. Kennedy, Laurie E. Grove, Nancy L. Bartlett, Amanda F. Cashen

Research output: Contribution to journalLetterpeer-review

12 Scopus citations
Original languageEnglish
Pages (from-to)506-507
Number of pages2
JournalLeukemia and Lymphoma
Issue number3
StatePublished - Mar 2012

Cite this